Effects of a New Bladder Cancer Treatment
Author Information
Author(s): Chade Daher C, Borra Ricardo C, Nascimento Ivan P, Villanova Fabiola E, Leite Luciana C, Andrade Enrico, Srougi Miguel, Ramos Kátia L, Andrade Priscila M
Primary Institution: University of São Paulo, São Paulo, Brazil
Hypothesis
Can recombinant BCG expressing pertussis toxin improve immune response and reduce tumor size in bladder cancer models?
Conclusion
The study found that rBCG-S1PT significantly reduced bladder tumor volume compared to BCG and PBS treatments.
Supporting Evidence
- rBCG-S1PT treatment resulted in a significant reduction in bladder weight compared to BCG and PBS.
- Increased levels of TNF-α were observed in both BCG and rBCG-S1PT treated groups.
- Only the rBCG-S1PT group showed a significant increase in IL-10 levels compared to controls.
Takeaway
Researchers tested a new treatment for bladder cancer and found it worked better than the standard treatment.
Methodology
The study involved treating C57BL/6 mice with either BCG, rBCG-S1PT, or PBS and measuring bladder weight and cytokine levels after tumor implantation.
Limitations
The study was conducted in a preclinical model, which may not fully replicate human responses.
Participant Demographics
Ninety female C57BL/6 mice aged six to eight weeks.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website